CatalYm Unveils Promising Phase 2 GDFATHER-NEO Data: Visugromab Enhances Anti-Tumor Activity with PD-1 Inhibition in Neoadjuvant Muscle-Invasive Bladder Cancer CatalYm, a pioneering biotechnology company recognized globally for its focus on neutralizing Growth Differentiation Factor-15 (GDF-15) in cancer and cachexia, has…
raditional Medicine Gains Prominence at World Health Summit 2025 For the first time in its history, the World Health Summit in 2025 highlighted traditional medicine as a core topic, with two dedicated sessions held in Berlin, Germany. These sessions underscored…
Chemist Lutz Ackermann Honored With Bayer Foundation’s Hansen Family Award; Four Young Researchers Receive Early Excellence in Science Awards Georg-August University Göttingen chemist Prof. Dr. Lutz Ackermann has been awarded the €75,000 Hansen Family Award from the Bayer Foundation for…
CVS Health Expands Access to Affordable Fertility Treatments Nationwide CVS Health (NYSE: CVS) has announced a major step toward improving access to fertility care and making fertility treatments more affordable for Americans. Through its CVS Specialty Pharmacy network and more…
Novartis’ Fabhalta® (Iptacopan) Achieves Positive Phase III Results, Marking Major Progress in Slowing Kidney Function Decline in Patients With IgA Nephropathy Novartis announced encouraging final results from its pivotal Phase III APPLAUSE-IgAN clinical trial, evaluating the investigational oral therapy Fabhalta®…
bioAffinity Technologies Restores Nasdaq Compliance, Strengthening Path Toward Long-Term Growth bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company dedicated to advancing early-stage cancer diagnostics, announced that it has successfully regained compliance with all Nasdaq Capital Market continued listing requirements.…
Viatris Expands CNS Portfolio in Japan with Acquisition of Aculys Pharma, Gaining Exclusive Rights to Pitolisant and Spydia® Viatris Inc. (Nasdaq: VTRS), a leading global healthcare company, today announced the successful acquisition of Aculys Pharma, Inc., a clinical-stage biopharmaceutical company…
argenx to Present Comprehensive Immunology Data at 2025 AANEM Annual Meeting and MGFA Scientific Session argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to improving the lives of people with severe autoimmune diseases, will present a wide…
Sanofi Establishes Montpellier as the Global Hub for Translational Research in Autoimmune Diseases Sanofi has announced the launch of a Translational Center of Excellence in Montpellier, a first-of-its-kind initiative developed in close partnership with the Immun4Cure University Hospital Institute (IHU…
Merck Presents New Phase 3 Data on Investigational Two-Drug HIV Regimen Doravirine/Islatravir (DOR/ISL) Showing Minimal Impact on Weight, Body Composition, and Lipid Levels Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced new results from its Phase…
AbbVie Announces FDA Approval of Updated RINVOQ® (upadacitinib) Indication for Inflammatory Bowel Disease NORTH CHICAGO, Ill., Oct. 13, 2025 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug…
Neurology Publication Demonstrates 95% Reduction in Mortality Risk with Pyrimidine Nucleos(t)ide Therapy in Patients with Thymidine Kinase 2 Deficiency (TK2d) UCB, a global biopharmaceutical company focused on the discovery and development of innovative treatments for serious diseases, today announced the…
